Provided by Tiger Trade Technology Pte. Ltd.

Summit Therapeutics PLC

13.62
-0.1100-0.80%
Pre-market: 13.50-0.1197-0.88%05:39 EDT
Volume:5.43M
Turnover:73.87M
Market Cap:10.87B
PE:-12.19
High:13.73
Open:13.51
Low:13.44
Close:13.73
52wk High:29.23
52wk Low:12.07
Shares:797.75M
Float Shares:152.34M
Volume Ratio:0.87
T/O Rate:3.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1177
EPS(LYR):-1.4439
ROE:-192.50%
ROA:-101.61%
PB:17.25
PE(LYR):-9.43

Loading ...

Summit Therapeutics Inc Stock (SMMT) Moved Up by 8.95% on Aug 26: Drivers Behind the Movement

TradingKey
·
Aug 26

Sector Update: Healthcare Stocks Lean Lower Pre-Bell Wednesday

MT Newswires Live
·
Aug 26

Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday Amid Inflation Data Release

MT Newswires Live
·
Aug 26

Summit Therapeutics Says Partner's Potential Biliary Tract Cancer Treatment Meets Primary, Secondary Endpoints

MT Newswires Live
·
Aug 26

Summit: Akeso reports ‘positive’ results from Phase III HARMONi-GI11 study

TIPRANKS
·
Aug 26

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China

THOMSON REUTERS
·
Aug 26

Summit Therapeutics - Study Meets Key Secondary Endpoints of Pfs and Orr

THOMSON REUTERS
·
Aug 26

Summit Says FDA Sets Nov. 14, 2026 Action Date for Ivonescimab Lung Cancer Filing

Reuters
·
Aug 25

Summit Therapeutics falls -8.5%

TIPRANKS
·
Aug 17

EV targets set to be watered down

cityam
·
Aug 14

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sutro Biopharma (STRO), Summit Therapeutics (SMMT) and Altimmune (ALT)

TIPRANKS
·
Aug 13

U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte

Reuters
·
Aug 13

Summit Partner Akeso Wins China NMPA Approval for Ivonescimab-Chemo in First-Line Squamous NSCLC

Reuters
·
Aug 12

Summit Gains After Partner Akeso Secures China Nod for Lung Cancer Combo

Reuters
·
Aug 12

Ivonescimab in Combination with Chemotherapy Approved in China by Nmpa for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer

THOMSON REUTERS
·
Aug 12

Summit Therapeutics Inc. : Leerink Partners Raises to Market Perform from Underperform; Raises Target Price to $13 from $12

THOMSON REUTERS
·
Aug 12

China's Automakers Capture Three Spots in UK July Best-Selling Top Ten

Deep News
·
Aug 06

Barclays Remains a Hold on Summit Therapeutics (SMMT)

TIPRANKS
·
Aug 06

Summit announces expansion of development program for ivonescimab

TIPRANKS
·
Aug 05

Summit Therapeutics - Initiates Global Phase Ii/Iii Harmoni-Gu1 Trial of Ivonescimab in Bladder Cancer

THOMSON REUTERS
·
Aug 05